Actinium-225 in Targeted Alpha Therapy
The utilization of actinium-225 ( Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of Ac production methods, various preclinical investigations, and several clinic...
Saved in:
| Published in: | Journal of medical physics Vol. 49; no. 2; pp. 137 - 147 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
India
Medknow Publications & Media Pvt. Ltd
01-04-2024
Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The utilization of actinium-225 (
Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of
Ac production methods, various preclinical investigations, and several clinical studies. Currently, there is a growing number of compounds labeled with
Ac that are being developed and tested in clinical trials. In response to the increasing demand for this nuclide, production facilities are either being built or have already been established. This article offers a concise summary of the present state of clinical advancements in compounds labeled with
Ac. It outlines various processes involved in the production and purification of
Ac to cater to the growing demand for this radionuclide. The article examines the merits and drawbacks of different procedures, delves into preclinical trials, and discusses ongoing clinical trials. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ISSN: | 0971-6203 1998-3913 |
| DOI: | 10.4103/jmp.jmp_22_24 |